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T he percutaneous treatment of coronary bifurcation lesions is, together with the treatment of lesions in degenerate saphenous vein grafts and chronic 
occlusions, one of the biggest challenges that an inter-
ventional cardiologist faces in daily practice. Several 
techniques for treating bifurcations have been described 
in addition to algorithms to indicate these techniques 
based on the calibre of the secondary branch and its 
angulation on the level of lesion involvement, but so 
far none has surpassed the simplicity of the provisional 
technique. In this issue of the Revista Brasileira de 
Cardiologia Invasiva (RBCI), in an excellent editorial, 
Buysschaert and Verheye from the Antwerp Cardiovas-
cular Institute, ZNA Middelheim (Antwerp, Belgium), 
explain the current consensus on the treatment of bifur-
cations and go beyond this, when they discuss whether 
post-dilation with kissing-balloon in the provisional 
technique should be performed and whether systematic 
pre-dilation of the side branch, particularly in complex 
bifurcation lesions, is recommended. They discuss the 
article by Costa et al. of the Instituto Dante Pazzanese 
de Cardiologia (São Paulo, SP, Brazil), which evaluated 
the impact of side branch pre-dilation in true bifurca-
tion lesions, with side branch lesions extending 5 mm 
beyond the ostium. They conclude the discussion by 
recommending a scenario in which they believe side 
branch pre-dilation should be indicated.
In another excellent editorial, Nakagawa and Ikeno 
from the Falk Cardiovascular Research Center, School 
of Medicine, Stanford University (Stanford, CA, USA), 
introduce us to the world of drug-eluting balloons. They 
comment on why the drug-eluting balloons approved 
for clinical use in Europe only use the drug paclitaxel 
as a neointimal proliferation inhibitor and describe 
the new sirolimus-eluting balloon, which is still in the 
experimental phase. They explain the importance of 
bench testing to detect the capacity of the released 
drug to infiltrate the arterial wall, to quantify the drug, 
and to verify whether it remains in the deeper layers 
of the vessel. They show the key role of the excipient 
as a method of antiproliferative drug delivery by the 
balloon and the need to prove the effectiveness of bal-
loons in preclinical studies. In this regard, they discuss 
the original work by Takimura et al. from the Instituto 
do Coração do Hospital das Clínicas da Faculdade de 
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Medicina da Universidade de São Paulo (São Paulo, SP, 
Brazil), who observed different neointimal responses, 
as assessed by optical coherence tomography and 
histopathology, of various excipient:drug formulations 
of the sirolimus-eluting balloon in an animal model. 
They complement their recommendations by noting 
that additional long-term data and pharmacokinetics 
evaluation are some of the steps that must be taken 
before performing clinical trials.
Other original studies were also pu blished in this 
issue of RBCI. Zago et al., from the Hospital de Clínicas 
de Porto Alegre (Porto Alegre, RS, Brazil), identified 
genes involved in smooth muscle cell structural and 
functional protein synthesis associated with neointimal 
hyperplasia in human atheromatous plaques obtained 
by guided atherectomy after coronary stent implanta-
tion. The finding that the atheromatous plaque has 
a significantly inherent predisposition to neointimal 
formation before stenting could pave the way for the 
development of new antiproliferative drugs in the 
search for a definitive solution to coronary restenosis. 
Abreu-Silva et al., from the Cardiovascular Research 
Center (São Paulo, SP, Brazil), present results of the 
PAX-B study, an international multicentre study that 
evaluated a non-polymeric paclitaxel-eluting stent in 
a complex angiographic scenario, with angiographic 
follow-up at nine months and clinical follow-up after 
12 months. In an interesting discussion, they debate 
the problems caused by polymers, but recognise their 
advantage in regulating the release kinetics of anti-
proliferative drugs, which are crucial for neointimal 
hyperplasia suppression, as well as tested alternatives for 
non-polymeric stents, such as the structural modification 
of the abluminal surface of metal struts.
Other articles complement this issue of RBCI with 
topics of great interest, such as the adjunctive use of 
fondaparinux in percutaneous coronary intervention in 
patients with acute coronary syndrome, the ten-year 
prognosis of young patients with coronary artery disease 
treated percutaneously, the current results of percuta-
neous coronary intervention in diabetic patients, the 
association between oral health and lesions detected 
on coronary angiography, the approach to non-aortic 
ostial coronary lesions using the Szabo technique, 
Chaves
Treatment of Coronary Bifurcations
Rev Bras Cardiol Invasiva. 
2012;20(2):117-8
118
the treatment of complicated type B aortic dissection, 
and the initial experience of PDA closure using the 
Amplatzer® Vascular Plug II.
Finally, we would like to communicate that the logo 
of the Brazilian Society of Interventional Cardiology has 
been updated and will, from this issue onward, replace 
the previous logo on the cover and in institutional 
communications published in RBCI.
Enjoy your reading!
Áurea J. Chaves 
Editor
